Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical United States Medicare

CMS Considering Part D Plan Partnerships With Medicare ACOs

  • News

Executive Summary

The agency is considering an “incentive model” that would allow Medicare’s accountable care organizations to collaborate with Part D plans, CMS Deputy Administrator Patrick Conway says.

You may also be interested in...



Medicare Risk-Sharing Contracts: A More Feasible Drug Cost Solution?

Duke’s Mark McClellan made a strong pitch for such contracting during a Capitol Hill debate on cost control with Johns Hopkins’ Gerard Anderson.

Insurer Seeks To Recover ‘Illegal’ Daraprim Overcharges Due To Obstruction Of Generics

Proposed class action lawsuit by Blue Cross Blue Shield of Minnesota against Vyera Pharmaceuticals could set a precedent for other health insurer actions against manufacturers.

Tie Goes To The Nominee: Becerra Heads To Senate Floor

Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical United States Medicare
UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By